These results further confirmed that MTHFD2 upregulates PD‐L1 by activating the JAK/STAT signalling pathway, which suggests that combining MTHFD2 inhibitors with PD‐L1 inhibitors may be a novel immunotherapy for BC and warrants further investigation. This evidence concerns the gene MTHFD2 and breast cancer.